BeiGene, Ltd. (6160.HK)
| Previous Close | 99.950 |
| Open | 101.500 |
| Bid | 99.900 x 0 |
| Ask | 99.950 x 0 |
| Day's Range | 98.700 - 101.900 |
| 52 Week Range | 75.450 - 148.900 |
| Volume | |
| Avg. Volume | 1,387,651 |
| Market Cap | 141.494B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
SAN MATEO, Calif., May 08, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the first quarter 2024 and business highlights.
- CNW Group
Biotech Leader, BeiGene, Inaugurates Office in Toronto, Canada
BeiGene Canada, the country affiliate of global oncology company BeiGene, specializing in the discovery and development of novel, affordable, and accessible oncology medications, has opened its first office in Canada. Situated in downtown Toronto, the new office space will be the Canadian headquarters where the company will work to extend the boundaries of 'the possible,' fulfilling BeiGene's promise of delivering best-in-class, innovative treatments to the Canadian cancer community.
- Business Wire
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.
